R&D Improving treatment for high-risk cataract surgery Cataracts rank among the most prevalent age-related ailments.
Patients Developing bold medicines to preserve vision and transform t... My training as a clinical ophthalmologist and retinal surgeon led me to a career dedicated to developing better therapies for people suffering from debilitating eye diseases and the many co
Partner Content Partner Content Industry news with an exclusive interview by from Aerie Phar... Ophthalmic Drugs
Partner Content Partner Content Europe’s Leading Ophthalmic Conference is Just 1 week away Ophthalmic Drugs
Partner Content Partner Content SMi’s Europe’s Leading Ophthalmic Conference is only 2 weeks... Ophthalmic Drugs
Partner Content Partner Content SMi’s Europe’s Leading Ophthalmic Conference is only 3 weeks... Europe's Leading Ophthalmic Conference
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
